12:00 PM EDT, 06/28/2024 (MT Newswires) -- Agenus ( AGEN ) shares were up more than 6% in recent Friday trading after the company posted results from an investigator-sponsored trial of botensilimab and balstilimab in the neoadjuvant setting for colon cancer.

The company said 78% of microsatellite stable patients in the NEST-2 cohort achieved at least 50% tumor regression, with 56% reaching complete pathologic response.

"The rapid and complete resolution of aggressive MSS colorectal cancer tumors observed in this study is unprecedented in the field," said Pashtoon Kasi, the originator of the study.

The data were presented at the European Society for Medical Oncology Gastrointestinal Cancers Congress in Munich, Germany.

Price: 14.98, Change: +0.86, Percent Change: +6.12